The results revealed that both shRNAs markedly deleted FBXO22 expression (Fig. 1C), and FBXO22 knockdown inhibited cell growth and clonogenicity in the primary AML cells (Fig. 1D, E). This evidence concerns the gene FBXO22 and acute myeloid leukemia.